$CGEM
Cullinan Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024093320 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.35M $13.77M
YoY Change 21.58% 34.85%
% of Gross Profit
Research & Development $35.51M $36.26M
YoY Change 4.98% 32.38%
% of Gross Profit
Depreciation & Amortization $76.00K $77.00K
YoY Change -5.0% -4.94%
% of Gross Profit
Operating Expenses $48.86M $50.03M
YoY Change 9.04% 33.03%
Operating Profit -$48.86M -$50.03M
YoY Change 7.98% 33.03%
Interest Expense $8.384M $8.071M
YoY Change 42.59% 51.71%
% of Operating Profit
Other Income/Expense, Net -$89.00K -$72.00K
YoY Change -149.44% -204.35%
Pretax Income -$40.56M -$42.03M
YoY Change 3.51% 30.47%
Income Tax
% Of Pretax Income
Net Earnings -$40.56M -$42.03M
YoY Change 3.51% 30.47%
Net Earnings / Revenue
Basic Earnings Per Share -$0.69 -$0.75
Diluted Earnings Per Share -$0.69 -$0.75
COMMON SHARES
Basic Shares Outstanding 57.98M 57.63M
Diluted Shares Outstanding 58.34M 55.05M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $578.1M $662.5M
YoY Change 23.94% 34.71%
Cash & Equivalents $102.1M $115.0M
Short-Term Investments $476.0M $547.5M
Other Short-Term Assets $13.96M $15.30M
YoY Change 35.54% 137.75%
Inventory
Prepaid Expenses $13.96M $15.30M
Receivables
Other Receivables
Total Short-Term Assets $592.0M $677.8M
YoY Change 24.19% 36.04%
LONG-TERM ASSETS
Property, Plant & Equipment $760.0K $836.0K
YoY Change -28.71% -27.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $57.98M
YoY Change 329.45%
Other Assets $460.0K $460.0K
YoY Change 0.22% 0.22%
Total Long-Term Assets $61.22M $3.417M
YoY Change 240.18% -85.61%
TOTAL ASSETS
Total Short-Term Assets $592.0M $677.8M
Total Long-Term Assets $61.22M $3.417M
Total Assets $653.3M $681.2M
YoY Change 32.05% 30.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.115M $1.555M
YoY Change 122.4% -37.63%
Accrued Expenses $20.83M $20.71M
YoY Change -0.55% 33.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.20M $23.48M
YoY Change 3.24% 19.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.188M $1.519M
YoY Change -50.5% -44.44%
Total Long-Term Liabilities $1.188M $1.519M
YoY Change -50.5% -44.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.20M $23.48M
Total Long-Term Liabilities $1.188M $1.519M
Total Liabilities $25.39M $25.00M
YoY Change -1.92% 11.54%
SHAREHOLDERS EQUITY
Retained Earnings -$320.6M -$280.0M
YoY Change 81.07% 103.11%
Common Stock $947.5M $936.7M
YoY Change 46.46% 46.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $627.9M $656.2M
YoY Change
Total Liabilities & Shareholders Equity $653.3M $681.2M
YoY Change 32.05% 30.51%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$40.56M -$42.03M
YoY Change 3.51% 30.47%
Depreciation, Depletion And Amortization $76.00K $77.00K
YoY Change -5.0% -4.94%
Cash From Operating Activities -$34.14M -$36.29M
YoY Change 0.0% 17.05%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $19.88M -$185.1M
YoY Change -146.27% -1622.43%
Cash From Investing Activities $19.88M -$185.1M
YoY Change -146.28% -1628.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.325M 262.2M
YoY Change 1104.55% 579.23%
NET CHANGE
Cash From Operating Activities -34.14M -36.29M
Cash From Investing Activities 19.88M -185.1M
Cash From Financing Activities 1.325M 262.2M
Net Change In Cash -12.94M 40.79M
YoY Change -83.2% 107.01%
FREE CASH FLOW
Cash From Operating Activities -$34.14M -$36.29M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$34.14M -$36.29M
YoY Change 0.0% 16.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001789972
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
cgem Operating Lease Commence Date
OperatingLeaseCommenceDate
2018-02-01
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-06-30
us-gaap Profit Loss
ProfitLoss
-90355000
us-gaap Share Based Compensation
ShareBasedCompensation
18760000
us-gaap Share Based Compensation
ShareBasedCompensation
15179000
cgem Amortization Accretion On Marketable Securities
AmortizationAccretionOnMarketableSecurities
-7031000
cgem Amortization Accretion On Marketable Securities
AmortizationAccretionOnMarketableSecurities
-3516000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
153000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
153000
cgem Non Cash Contributions From Noncontrolling Interests
NonCashContributionsFromNoncontrollingInterests
0
cgem Non Cash Contributions From Noncontrolling Interests
NonCashContributionsFromNoncontrollingInterests
4000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2181000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1161000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-938000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-169000
cgem Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-3933000
cgem Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-178000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-4282000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-74538000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-82003000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
456298000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
170592000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
284142000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
198094000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
208000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-172156000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27294000
cgem Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs
IssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
-262652000
cgem Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs
IssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
-38388000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39856
dei Entity Registrant Name
EntityRegistrantName
CULLINAN THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3879991
dei Entity Address Address Line1
EntityAddressAddressLine1
One Main Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1350
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address Country
EntityAddressCountry
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
410-4650
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
CGEM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
57976641
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115021000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98434000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
547474000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
368633000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15304000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
13124000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
677799000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
480191000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
836000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
989000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2121000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2543000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
460000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
459000
CY2024Q2 us-gaap Assets
Assets
681216000
CY2023Q4 us-gaap Assets
Assets
484182000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1555000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2493000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20706000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24204000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1215000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1440000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
23476000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28137000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1519000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2150000
CY2024Q2 us-gaap Liabilities
Liabilities
24995000
CY2023Q4 us-gaap Liabilities
Liabilities
30287000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
647500
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
647500
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
647500
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
647500
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57871638
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57871638
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42900083
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42900083
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
936724000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
654685000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-476000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-129000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-280033000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-200857000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
656221000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
453703000
CY2024Q2 us-gaap Minority Interest
MinorityInterest
0
CY2023Q4 us-gaap Minority Interest
MinorityInterest
192000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
656221000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
453895000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
681216000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
484182000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36259000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27391000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66905000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
79487000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13768000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10214000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26111000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20874000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
50027000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
37605000
us-gaap Operating Expenses
OperatingExpenses
93016000
us-gaap Operating Expenses
OperatingExpenses
100361000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-50027000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-37605000
us-gaap Operating Income Loss
OperatingIncomeLoss
-93016000
us-gaap Operating Income Loss
OperatingIncomeLoss
-100361000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
8071000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5322000
us-gaap Investment Income Interest
InvestmentIncomeInterest
13764000
us-gaap Investment Income Interest
InvestmentIncomeInterest
9830000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-72000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
69000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-116000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
176000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-42028000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-32214000
us-gaap Profit Loss
ProfitLoss
-79368000
us-gaap Profit Loss
ProfitLoss
-90355000
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-192000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-179000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-42028000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-32214000
us-gaap Net Income Loss
NetIncomeLoss
-79176000
us-gaap Net Income Loss
NetIncomeLoss
-90176000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-42028000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-32214000
us-gaap Profit Loss
ProfitLoss
-79368000
us-gaap Profit Loss
ProfitLoss
-90355000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-145000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-383000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-347000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
976000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-42173000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-32597000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-79715000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-89379000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-192000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-179000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42173000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32597000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-79523000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-89200000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55052000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55052000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39952000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39952000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49031000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49031000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40315000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40315000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
453895000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1085000
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8227000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-202000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-37340000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
425665000
CY2024Q2 cgem Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs
IssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
262652000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3336000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
10533000
CY2024Q2 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
3792000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-145000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-42028000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
656221000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
535029000
CY2023Q1 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
179000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
36000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7259000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1359000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-58141000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
485649000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
38388000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
214000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7920000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-383000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-32214000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
499574000
us-gaap Profit Loss
ProfitLoss
-79368000
cgem Proceeds From Net Issuance Of Common Stock Under Equity Based Compensation Plans
ProceedsFromNetIssuanceOfCommonStockUnderEquityBasedCompensationPlans
4421000
cgem Proceeds From Net Issuance Of Common Stock Under Equity Based Compensation Plans
ProceedsFromNetIssuanceOfCommonStockUnderEquityBasedCompensationPlans
178000
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
3792000
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
0
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
1825000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
263281000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40391000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
16587000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14318000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
98434000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
156152000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
115021000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
141834000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-2274000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4708000
CY2024Q2 us-gaap Convertible Debt
ConvertibleDebt
0
CY2023Q2 us-gaap Convertible Debt
ConvertibleDebt
175000
CY2024Q2 cgem Cash Equivalents Short Term Investments And Interest Recivable
CashEquivalentsShortTermInvestmentsAndInterestRecivable
664900000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
547950000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
491000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
547474000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
368762000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
251000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
380000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
368633000
CY2024Q2 cgem Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
12021000
CY2023Q4 cgem Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
8434000
CY2024Q2 cgem Due To Taiho Under Collaboration Agreement Net
DueToTaihoUnderCollaborationAgreementNet
2359000
CY2023Q4 cgem Due To Taiho Under Collaboration Agreement Net
DueToTaihoUnderCollaborationAgreementNet
7869000
CY2024Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4106000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
6987000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2220000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
914000
CY2024Q2 cgem Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
20706000
CY2023Q4 cgem Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
24204000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote and to receive dividends when and if declared by the board of directors of the Company.
CY2024Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2024Q2 cgem Number Of Shares Of Common Stock Percentage
NumberOfSharesOfCommonStockPercentage
0.0999
CY2024Q2 cgem Increase In Number Of Shares Of Preferred Stock Percentage
IncreaseInNumberOfSharesOfPreferredStockPercentage
0.1999
cgem Schedule Of Development Subsidiaries And Their Product Candidates
ScheduleOfDevelopmentSubsidiariesAndTheirProductCandidates
<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:51.32%;"></td> <td style="width:2.86%;"></td> <td style="width:21.48%;"></td> <td style="width:2.86%;"></td> <td style="width:21.48%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;">Ownership Interest as of</span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Product Candidate</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CLN-619</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CLN-049</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CLN-617</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td> </tr> </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2024, Cullinan paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to acquire shares of its CLN-619 development subsidiary that were held by noncontrolling interests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrants</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had potentially issuable shares of common stock related to unexercised pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of the Company’s common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The pre-funded warrants may be exercised at the option of the holder at any time, subject to certain limitations. The exercise price and the number of shares are subject to adjustment for certain dividend payments and upon reclassification, exchange, combination or substitution of the shares of common stock. The pre-funded warrants expire in April 2054 if they have not been exercised by that time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cullinan determined that the pre-funded warrants should be equity-classified. The Company also determined that the pre-funded warrants should be included in the weighted-average shares used in computing basic net loss per share attributable to common stockholders of Cullinan.</span></p>
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10533000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7920000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18760000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15179000
us-gaap Royalty Expense
RoyaltyExpense
0
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
900000
cgem Operating Lease Payments Proceeds
OperatingLeasePaymentsProceeds
1024000
cgem Operating Lease Payments Proceeds
OperatingLeasePaymentsProceeds
875000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
714000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1461000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
871000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3046000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
312000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2734000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M6D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.109
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-42028000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-32214000
us-gaap Net Income Loss
NetIncomeLoss
-79176000
us-gaap Net Income Loss
NetIncomeLoss
-90176000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55052000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55052000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39952000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39952000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49031000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49031000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40315000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40315000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15072000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15136000

Files In Submission

Name View Source Status
0000950170-24-093320-index-headers.html Edgar Link pending
0000950170-24-093320-index.html Edgar Link pending
0000950170-24-093320.txt Edgar Link pending
0000950170-24-093320-xbrl.zip Edgar Link pending
cgem-20240630.htm Edgar Link pending
cgem-20240630.xsd Edgar Link pending
cgem-ex31_1.htm Edgar Link pending
cgem-ex31_2.htm Edgar Link pending
cgem-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
cgem-20240630_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending